INS and Hypoglycemia: Clinical trials have shown that BBR significantly promotes insulin secretion in the hyperglycemic state without affecting human basal insulin secretion; therefore, some researchers believe that BBR is an insulin secretagogue, and is different from other insulin secretagogues, because BBR only effectively reduces blood glucose levels under hyperglycemic conditions without causing hypoglycemia targeting KCNH6 channels (Zhao et al., 2021).